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Abstract
Purpose of review—Summarize recent developments for HIV-associated malignancies 
(HIVAM) in low- and middle-income countries (LMIC) with particular focus on sub-Saharan 
Africa (SSA).
Recent findings—Antiretroviral therapy (ART) scale-up is leading to epidemiologic transitions 
in LMIC similar to high-income countries, with aging and growth of HIV-infected populations, 
declining infectious deaths, increasing cancer deaths, and transitions from AIDS-defining cancers 
(ADC) to non-AIDS defining cancers (NADC). Despite ART scale-up, HIVAM burden remains 
high including enormous ADC burden in SSA. For Kaposi sarcoma (KS), patients treated with 
ART and chemotherapy can experience good outcomes even in rural SSA, but KS heterogeneity 
remains insufficiently understood including virologic, immunologic, and inflammatory features 
which may be unique to LMIC. For cervical cancer, scale-up of prevention efforts including 
vaccination and screening is underway, with benefits already apparent despite continuing high 
disease burden. For non-Hodgkin lymphoma (NHL), curative treatment is possible in the ART era 
even in SSA, and multifaceted approaches can improve outcomes further. For many other 
prevalent HIVAM, care and research efforts are being established to guide treatment and 
prevention specifically in LMIC.
Summary—Sustained investment for HIVAM in LMIC can help catalyze a cancer care and 
research agenda which benefits HIV-positive and HIV-negative patients worldwide.
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Introduction
Just as the worldwide HIV pandemic disproportionately affects populations in low- and 
middle-income countries (LMIC), especially sub-Saharan Africa (SSA), so too does the 
parallel epidemic of HIV-associated malignancies (HIVAM) which are often the most 
common cancers overall in highly HIV-endemic countries. For HIV itself, the last two 
decades have witnessed a remarkable global effort for prevention, treatment, and research, 
resulting from worldwide advocacy and multilateral investment, with a reach that now 
extends to some of the remotest villages in some of the world’s poorest countries. A 
comparable effort for HIVAM is taking shape. In this review, we summarize recent 
developments for HIVAM in LMIC, highlighting progress, challenges, and opportunities in 
this emerging field.
Epidemiology
The global HIV epidemic is concentrated in LMIC, and SSA specifically, with 69% of the 
worldwide HIV-infected population living in this region in 2015 [1]. In SSA, public sector 
ART provision in most countries began in the mid-2000s, with 11.8 million individuals now 
receiving ART or 46% or those living with HIV. Importantly, with accumulating evidence 
demonstrating individual- and population-level benefits of earlier ART, World Health 
Organization (WHO) guidelines for ART eligibility in LMIC have become progressively 
more inclusive. All HIV-infected individuals are now recommended to receive ART 
irrespective of CD4 count [2], although many countries have yet to implement treating all 
HIV-positive people due to resource limitations and logistical issues. As a result, despite 
dramatic increases in ART availability worldwide, the coverage gap in most LMIC remains 
considerable. Moreover, achievements in ART scale-up are fragile and conditional on 
ongoing commitments by governments and external donors, with potential for gains to be 
reversed if commitments are not firm. Finally, despite ambitious targets and incremental 
progress to provide earlier ART, HIV-infected individuals in LMIC still typically initiate 
ART with advanced immunosuppression [3], accruing significant risk of morbidity 
compared to asymptomatic patients treated before CD4 count depletion or HIV-related 
complications. LMIC therefore have substantial HIV-infected populations who still cannot 
access timely HIV diagnosis and treatment, similar to early years before public sector ART 
availability, along with large numbers of patients having well controlled HIV on long-term 
ART, for whom epidemiologic transitions toward chronic non-communicable disease (NCD) 
complications of HIV are occurring as in resource-rich settings.
With respect to HIVAM epidemiology, data from high-income countries demonstrate that the 
proportion of HIV-related deaths due to cancer is increasing [4], HIVAM are transitioning 
from AIDS-defining cancers (ADC) to non-AIDS defining cancers (NADC) [5], and CD4 
count and HIV control at cancer diagnosis are improving even for patients with ADC [6]. 
However, several factors make it difficult to fully assess the degree to which trends in 
resource-rich settings are replicated in LMIC, even aside from less mature ART coverage. 
There are severe deficits in cancer registration in LMIC, particularly SSA and even for 
registries contributing to WHO global cancer estimates, including low population coverage, 
significant urban bias, and low data quality [7**]. Even in well enumerated HIV cohorts 
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retained in care on chronic ART, ascertainment of cancer diagnoses is poor [8*]. Diagnostic 
pathology in SSA is also limited, and often under-utilized when it exists [9]. Even for 
superficial tumors which can be visualized and often are diagnosed clinically in SSA, like 
Kaposi sarcoma (KS) and ocular surface squamous neoplasia (OSSN), clinical diagnosis 
performs poorly compared to pathology with positive predictive value less than 80% [10*, 
11*]. For more visceral tumors, not only pathology limitations but inadequate surgical or 
interventional capabilities to obtain diagnostic tissue results in these tumors also being 
underrepresented. In Malawi, investments to build and improve pathology infrastructure led 
to the ‘discovery’ of HIV-associated multicentric Castleman disease (MCD), which is 
scarcely reported from SSA and in Malawi was often misdiagnosed as lymphadenitis due to 
tuberculosis or HIV [12, 13*]. Finally, because cancer diagnosis and care are highly 
centralized in LMIC, there is significant referral bias affecting all cancer burden 
descriptions, such that tumors at the most indolent and fulminant ends of the clinical 
spectrum may be underrepresented, as patients may die before presenting to tertiary centers 
when severely ill or forego spending time and money to seek care for mild symptoms. Even 
in Botswana, a country with a relatively small population and high per capita resource level 
relative to many of its neighbors, as well as one of the region’s most successful national 
ART programs, a median 13-month delay has been documented from symptom onset to 
receipt of subspecialty oncology care across diverse cancer patients [14**].
Despite these caveats, data are emerging that ART availability in LMIC may be producing 
trends which at least partly resemble resource-rich settings. Perhaps not surprisingly, similar 
trends to high-income countries are most evident thus far in middle-income countries, where 
ART coverage and cancer diagnostic infrastructure are better than low-income countries. For 
instance, in Botswana, ART expansion has resulted in significant decreases in age-specific 
cancer risk for HIV-infected individuals [15**]. However, just as in resource-rich settings, 
when declining incidence is coupled to growth and aging of HIV-positive populations, 
HIVAM burden is static without significant declines. Similarly, in both China and Brazil, 
relative ADC declines and NADC increases are occurring as in high-income countries [16*, 
17*]. Conversely, in most of SSA, ADC still dominate with incidence declines most 
consistently observed for KS, although KS incidence remains high throughout the region 
and is often among the most frequent cancers overall [15**, 18*, 19*, 20, 21**, 22]. 
HIVAM are therefore unlikely to recede as a public health problem in LMIC in the near term 
despite ART scale-up. Studies from SSA have also suggested links between HIV and 
malignancies without well described associations with HIV in high-income countries. An 
example is esophageal squamous cell carcinoma which occurs with high frequency in much 
of SSA for reasons that remain unclear, and which has been associated with HIV in a case-
control study from Zambia [23*]. A linkage study between HIV and cancer registries in 
Uganda also suggested potentially novel associations between HIV and several tumors 
including kidney, thyroid, uterine, breast, and nasopharyngeal cancers [24]. More definitive 
regional epidemiologic studies are needed to prove or disprove these associations.
Kaposi sarcoma
As noted above, KS is the most frequent cancer in many SSA countries. Patients with HIV-
associated KS in SSA have higher mortality, higher risk of immune reconstitution 
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inflammatory syndrome (IRIS), and more frequently detectable Kaposi sarcoma-associated 
herpesvirus (KSHV) in peripheral blood than cohorts in resource-rich settings [25]. For KS, 
the KART study conducted in Durban remains the only clinical trial completed in SSA in the 
ART era, and demonstrated better tumor response but similar overall survival at one year for 
HIV-infected patients with primarily advanced KS treated with ART plus chemotherapy 
(ABV; doxorubicin, bleomycin, vincristine) compared with ART alone [26]. Two ongoing 
multinational studies co-sponsored by the AIDS Clinical Trials Group and AIDS 
Malignancy Consortium are evaluating treatment strategies for limited and advanced KS 
respectively [27, 28]. The limited KS trial is comparing ART alone to ART plus oral 
etoposide, and the advanced KS trial is comparing ART for all patients with oral etoposide, 
intravenous paclitaxel, or intravenous bleomycin plus vincristine. Final results from both 
studies will inform regional practice. Apart from clinical trials at urban SSA referral centers, 
we have demonstrated in Malawi that ART with chemotherapy (paclitaxel or bleomycin/
vincristine) can produce excellent outcomes even in extremely remote areas, when 
implemented using standardized algorithms with appropriate levels of support for nurses and 
clinical officers [29**]. In this cohort, anemia and low body mass index were significantly 
associated with worse survival.
Associations between anemia and poor outcomes are interesting given Malawi experience 
with MCD, which has been observed almost exclusively among HIV-infected individuals 
with excellent long-term HIV control on ART often without evident KS [12, 13*]. Patients 
with MCD have had severe illness including profound anemia with markedly elevated 
plasma KSHV levels, and have typically responded to chemotherapy but relapsed shortly 
after chemotherapy was discontinued with subsequently poor outcomes in the absence of 
rituximab availability. The association between anemia and worse survival for HIV-
associated KS raises questions as to whether concurrent MCD, KSHV-associated 
inflammatory cytokine syndrome (KICS), or a virologic, inflammatory, and/or immunologic 
milieu at least partially resembling these disorders, may occur in some KS patients in SSA 
and contribute to worse outcomes. Work in Uganda has suggested that immune activation 
via induction of indoleamine dioxygenase may be associated with reduced KS incidence in 
HIV-positive people [30*], and similar pathways might be implicated in differential 
outcomes for patients with KS. Overall, heterogeneity among HIV-associated KS patients in 
SSA, including development of IRIS, remains poorly understood, and numerous groups are 
working to define KS subtypes and clinical implications more clearly. In Malawi, our group 
demonstrated the possible existence of KS subtypes defined by KSHV transcription either 
limited to latency loci or extending across the viral genome [31]. Other groups have 
provided novel descriptions of pediatric KS [32**–34], a distinct form of KS frequently 
characterized by lymphadenopathy and peripheral blood cytopenias, which is highly 
geographically restricted to SSA where HIV and KSHV are prevalent and both often 
acquired during childhood [35**].
Cervical cancer
Cancers caused by human papillomavirus (HPV), particularly cervical cancer, exact an 
enormous toll in LMIC, and are unique among HIVAM in having established preventive 
interventions, including immunization against HPV and screening for dysplasia. Efforts to 
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optimize delivery of these measures in LMIC are ongoing, and in SSA are often 
piggybacked onto infrastructure developed for HIV care. Similar to ART scale-up, 
substantial progress can be achieved within relatively short periods with committed support 
for population-level implementation. In Rwanda, more than 90% coverage with HPV 
vaccine among school-age girls was achieved within five years of the national program 
being initiated [36**], and within two years HPV prevalence was lower among vaccinated 
versus unvaccinated girls [37**]. Just as in resource-rich settings, community education is 
paramount to optimize vaccine uptake, as evidenced in Kenya where higher teacher 
knowledge about HPV may be an important factor facilitating success of school-based 
immunization [38*]. Even with widespread availability of HPV vaccination, effects on HPV-
associated cancer incidence will not be immediate. Moreover, the quadrivalent vaccine 
which has been most widely adopted is less immunogenic in HIV-infected women with 
severe immunosuppression [39], and vaccination has yet to be applied in most LMIC to at-
risk populations other than school-age girls, including boys. The quadrivalent vaccine also 
provides limited protection against oncogenic HPV subtypes other than 16 and 18, with 
non-16/18 subtypes being responsible for approximately 20% of cervical cancer globally 
[40], although the proportion of cases attributable to 16/18 versus non-16/18 HPV subtypes 
does not appear to differ in SSA by HIV status [41**].
Vaccine scale-up must be accompanied by screening scale-up, for which high-level evidence 
exists that this can be implemented on a large scale using visual inspection with acetic acid 
(VIA) or HPV testing, with consequent mortality reductions related to cervical cancer [42, 
43]. Substantial progress in scaling up VIA has been made in many LMIC countries, for 
example Zambia, where a large national screening program has found an extremely high 
burden of high-grade dysplasia and cancer especially among women with HIV [44**, 45**]. 
Other methods to optimize screening are under evaluation, including evaluations of HPV 
testing specifically among HIV-positive women and use of self-collected specimens [46, 47]. 
As these efforts move forward, best practices for cervical cancer screening in LMIC will 
become better defined to achieve more immediate declines in disease-specific incidence and 
mortality, while longer-term effects of population-level HPV immunization are awaited.
Despite vaccination and screening, cervical cancer cases continue to occur, and treatment in 
SSA is made difficult by scarce or absent radiotherapy in many countries [48], as is typically 
required for women with stage IB2 or greater tumors who cannot be treated with surgical 
resection alone. Overall, cervical cancer treatment studies have been few, but the AIDS 
Malignancy Consortium has recently completed a study evaluating the feasibility of 
cisplatin-based chemoradiation specifically among HIV-infected women with locally 
advanced cervical cancer in Zimbabwe [49].
Non-Hodgkin lymphoma
While less frequent than KS or cervical cancer, non-Hodgkin lymphoma (NHL) is most 
commonly treated with curative intent in LMIC among HIVAM, building on experience in 
resource-rich settings showing that HIV-positive NHL patients can be treated with similar 
intensity and achieve similar outcomes to those without HIV in the ART era. Despite 
availability in LMIC of generic chemotherapy drugs which remain key components of NHL 
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treatment even in high-income countries, stock outs are common, supportive care is limited 
including often absent hematopoietic growth factors, infusional and higher-intensity 
regimens are often impractical, infectious complications during chemotherapy and anti-
infective prophylaxis strategies are poorly defined, and newer non-cytotoxic agents 
including rituximab are often not available. In Malawi, HIV-infected patients with 
aggressive NHL present with advanced bulky disease and poor performance status, although 
interestingly with less tumor bulk and shorter symptom durations than HIV-negative 
patients, perhaps reflecting primary care and referral networks established for HIV which 
are absent for HIV-uninfected populations [50*]. With appropriate monitoring and dose 
adjustment, even unselected HIV-infected patients can be treated with standard 
chemotherapy (CHOP; cyclophosphamide, doxorubicin, vincristine, prednisone), with 
comparable treatment intensity to HIV-negative patients, reasonably good outcomes, and 
deaths primarily related to relapsed/refractory NHL, although treatment-related mortality is 
also considerable. Outcomes are principally determined by NHL disease characteristics 
(international prognostic index score) rather than HIV status, and neutropenia is by far the 
most frequent toxicity among HIV-positive patients which might be easily addressed with 
greater availability of hematopoietic growth factors. Based on our experience and other 
similar reports from SSA [51–53], continued efforts to diagnose patients earlier, treat them 
with standardized protocols, improve supportive care, and incorporate newer non-cytotoxic 
therapies can likely increase cure rates substantially even for HIV-infected patients in highly 
resource-limited settings [54]. Strategies testing lower-intensity, oral, metronomic 
approaches are also under evaluation with some promising early experience [55, 56].
Other cancers
Many other HIVAM occur with appreciable frequency in LMIC, and many groups are 
developing research programs specifically focused on these. For instance, for conjunctival 
squamous cell carcinoma, efforts to screen HIV-infected patients in Kenya using toluidine 
blue staining have been described [57*], as well as suggestions that resection followed by 
brachytherapy may be well tolerated and associated with low recurrence rates in South 
Africa [58*]. However, given the relatively immature nature of the field overall, there are not 
major recent studies for other HIVAM in LMIC that would clearly merit inclusion in this 
review, although it is hoped that more data related to these tumors will soon be forthcoming.
Conclusion
The field of HIVAM in LMIC is in its infancy. Building on remarkable progress for HIV, 
there are encouraging initial efforts to define unique pathogenesis and best approaches to 
treatment and prevention for HIVAM in LMIC where burden is greatest. Continued 
investments for HIVAM in LMIC can also likely catalyze a broader cancer care and research 
agenda, with substantial benefits to HIV-positive and HIV-negative cancer patients 
worldwide.
Acknowledgments
We thank Toon van der Gronde for assistance with manuscript preparation.
Chinula et al. Page 6
Curr Opin HIV AIDS. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Financial support and sponsorship
LC, AM, and SG are supported by the Malawi Cancer Consortium (U54CA190152), AIDS Malignancy Consortium 
(U01CA121947), and Lineberger Comprehensive Cancer Center (P30CA016086). LC receives additional support 
from the Fogarty Global Health Fellows Program (R25TW009340). SG receives additional support through grants 
from the National Institutes of Health (K01TW009488, R21CA180815, P20CA210285). Support has also been 
provided by the Medical Education Partnership Initiative (U2GPS001965).
References
Papers of particular interest, published within the period of review (18 months from 1 Feb 
2015 until 1 Aug 2016) have been highlighted as follows: *of special interest **of 
outstanding interest
1. UNAIDS. AIDSinfo. Available at: http://aidsinfo.unaids.org/. (accessed 1 August 2016)
2. UNAIDS. 90–90–90: An ambitious treatment target to help end the AIDS epidemic. Available at: 
http://www.unaids.org/en/resources/documents/2014/90-90-90. (accessed 1 August 2016)
3. Avila D, Althoff KN, Mugglin C, et al. Immunodeficiency at the start of combination antiretroviral 
therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr. 2014; 65:e8–
16. [PubMed: 24419071] 
4. Bonnet F, Burty C, Lewden C, et al. Changes in cancer mortality among HIV-infected patients: the 
Mortalite 2005 Survey. Clin Infect Dis. 2009; 48:633–9. [PubMed: 19202627] 
5. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United 
States. J Natl Cancer Inst. 2011; 103:753–62. [PubMed: 21483021] 
6. Yanik EL, Achenbach CJ, Gopal S, et al. Changes in clinical context for Kaposi sarcoma and non-
Hodgkin lymphoma among HIV-infected people in the United States. J Clin Oncol. 2016 (in press). 
7**. Crocker-Buque T, Pollock AM. Appraising the quality of sub-Saharan African cancer registration 
systems that contributed to GLOBOCAN 2008: a review of the literature and critical appraisal. J 
R Soc Med. 2015; 108:57–67. This study critically appraises the quality of cancer registries in 
sub-Saharan Africa contributing to GLOBOCAN estimates. Population coverage across countries 
ranged from 2.3% to 100% with heavy urban bias in all registries, and 20 countries and 300 
million people having no cancer registration. Data quality from cancer registries included in 
GLOBOCAN was overall poor. [PubMed: 25721114] 
8*. Sengayi M, Spoerri A, Egger M, et al. Record linkage to correct under-ascertainment of cancers in 
HIV cohorts: The Sinikithemba HIV clinic linkage project. Int J Cancer. 2016; 139:1209–16. 
This study from South Africa demonstrates marked under-ascertainment of cancer diagnoses 
within a large HIV cohort, with a more than six-fold increase in estimated cancer incidence after 
cohort data were linked with data from geographically overlapping cancer registries. [PubMed: 
27098265] 
9. Adesina A, Chumba D, Nelson AM, et al. Improvement of pathology in sub-Saharan Africa. Lancet 
Oncol. 2013; 14:e152–7. [PubMed: 23561746] 
10*. Amerson E, Woodruff CM, Forrestel A, et al. Accuracy of Clinical Suspicion and Pathologic 
Diagnosis of Kaposi Sarcoma in East Africa. J Acquir Immune Defic Syndr. 2016; 71:295–301. 
This study in HIV clinics in Uganda and Kenya found only 77% positive predictive value for 
clinically suspected Kaposia sarcoma compared to final histologic diagnosis, highlighting a need 
to improve pathology and abandon clinical diagnosis for this disease. [PubMed: 26452066] 
11*. Gichuhi S, Macharia E, Kabiru J, et al. Clinical Presentation of Ocular Surface Squamous 
Neoplasia in Kenya. JAMA Ophthalmol. 2015; 133:1305–13. This study in Kenya found only 
54% positive predictive value for clinically suspected ocular surface squamous neoplasia 
compared to final histologic diagnosis, suggesting that malignant and benign conjunctival lesions 
are not reliably distinguished by clinical exam alone. [PubMed: 26378395] 
12. Gopal S, Fedoriw Y, Montgomery ND, et al. Multicentric Castleman’s disease in Malawi. Lancet. 
2014; 384:1158. [PubMed: 25241721] 
13*. Gopal S, Liomba NG, Montgomery ND, et al. Characteristics and survival for HIV-associated 
multicentric Castleman disease in Malawi. J Int AIDS Soc. 2015; 18:20122. This is the first 
clinical case series of multicentric Castleman disease reported from sub-Saharan Africa, where 
Chinula et al. Page 7
Curr Opin HIV AIDS. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
HIV and Kaposi sarcoma-associated herpesvirus are both prevalent, demonstrating late diagnosis, 
frequent misdiagnosis, severe illness, and high mortality for these patients. [PubMed: 26242311] 
14**. Brown CA, Suneja G, Tapela N, et al. Predictors of Timely Access of Oncology Services and 
Advanced-Stage Cancer in an HIV-Endemic Setting. Oncologist. 2016; 21:731–8. This study 
documents long delays between symptom onset and oncology care (median 13 months) in the 
high middle-income country of Botswana for a diverse group of cancer patients. Longitudinal 
engagement in HIV care for HIV-infected cancer patients did not appear to shorten delays in 
accessing specialized oncology care. [PubMed: 27053501] 
15**. Dryden-Peterson S, Medhin H, Kebabonye-Pusoentsi M, et al. Cancer Incidence following 
Expansion of HIV Treatment in Botswana. PLoS One. 2015; 10:e0135602. This study describes 
changing cancer incidence in one of the most mature antiretroviral therapy programs from sub-
Saharan Africa. Age-specific cancer risk declined in HIV-infected individuals between 2003 and 
2008, but growth and aging of the HIV-positive population resulted in unchanged HIV-associated 
malignancies burden over time. [PubMed: 26267867] 
16*. Yang J, Su S, Zhao H, et al. Prevalence and mortality of cancer among HIV-infected inpatients in 
Beijing, China. BMC Infect Dis. 2016; 16:82. This study decribes 7.7% of HIV-infected 
inpatients in Beijing being admitted with cancer from 2008 to 2013, with approximately two-
thirds of patients having non-AIDS defining cancers, and one-third having AIDS-defining 
cancers. [PubMed: 26883427] 
17*. Castilho JL, Luz PM, Shepherd BE, et al. HIV and cancer: a comparative retrospective study of 
Brazilian and U.S. clinical cohorts. Infect Agent Cancer. 2015; 10:4. This comparative study of 
HIV cohorts in the United States and Brazil from 1998 to 2010 demonstrates declining AIDS-
defining cancer rates but stable non-AIDS defining cancer rates in both settings. [PubMed: 
25685180] 
18*. Mutyaba I, Phipps W, Krantz EM, et al. A Population-Level Evaluation of the Effect of 
Antiretroviral Therapy on Cancer Incidence in Kyadondo County, Uganda, 1999–2008. J Acquir 
Immune Defic Syndr. 2015; 69:481–6. This ecological analysis from Uganda correlates 
increasing antiretorival therapy coverage with declining Kaposi sarcoma and gastric cancer rates, 
but significant declines in other tumor types were not observed. [PubMed: 25844696] 
19*. Rogena EA, Simbiri KO, De Falco G, et al. A review of the pattern of AIDS defining, HIV 
associated neoplasms and premalignant lesions diagnosed from 2000–2011 at Kenyatta National 
Hospital, Kenya. Infect Agent Cancer. 2015; 10:28. This retrospective review of HIV-associated 
malignancies from a national hospital in Kenya from 2000 to 2011 found continued 
predominance of AIDS-defining cancers, particularly Kaposi sarcoma, and conjunctival cancer 
being the most frequent non-AIDS defining cancer. [PubMed: 26306097] 
20. Msyamboza KP, Dzamalala C, Mdokwe C, et al. Burden of cancer in Malawi; common types, 
incidence and trends: national population-based cancer registry. BMC Res Notes. 2012; 5:149. 
[PubMed: 22424105] 
21**. Semeere A, Wenger M, Busakhala N, et al. A prospective ascertainment of cancer incidence in 
sub-Saharan Africa: The case of Kaposi sarcoma. Cancer Med. 2016; 5:914–28. This study 
attempts to overcome cancer registration deficiences in sub-Saharan Africa and provide credible 
estimates for Kaposi sarcoma incidence within large, well enumerated, HIV cohorts in Uganda 
and Kenya. From 2007 to 2012, the age-standardized Kaposi sarcoma incidence was more than 
300/100,000 person-years, highlighting a continued enormous burden athough incidence was 
lower among women, ART users, and those with higher CD4 counts. [PubMed: 26823008] 
22. Rohner E, Valeri F, Maskew M, et al. Incidence rate of Kaposi sarcoma in HIV-infected patients on 
antiretroviral therapy in Southern Africa: a prospective multicohort study. J Acquir Immune Defic 
Syndr. 2014; 67:547–54. [PubMed: 25393941] 
23*. Kayamba V, Bateman AC, Asombang AW, et al. HIV infection and domestic smoke exposure, but 
not human papillomavirus, are risk factors for esophageal squamous cell carcinoma in Zambia: a 
case-control study. Cancer Med. 2015; 4:588–95. This study from Zambia found a modest 
association between HIV and esophageal cancer (odds ratio 2.3) which was higher among 
patients younger than 60 years (odds ratio 4.3), suggesting a potentially novel link which requires 
confirmation between HIV and another high-frequency tumor in sub-Saharan Africa. [PubMed: 
25641622] 
Chinula et al. Page 8
Curr Opin HIV AIDS. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
24. Mbulaiteye SM, Katabira ET, Wabinga H, et al. Spectrum of cancers among HIV-infected persons 
in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer. 2006; 118:985–90. 
[PubMed: 16106415] 
25. Letang E, Lewis JJ, Bower M, et al. Immune reconstitution inflammatory syndrome associated 
with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS. 2013; 
27:1603–13. [PubMed: 23462220] 
26. Mosam A, Shaik F, Uldrick TS, et al. A randomized controlled trial of highly active antiretroviral 
therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with 
HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr. 2012; 60:150–7. 
[PubMed: 22395672] 
27. ClinicalTrials.gov. Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With 
Immediate Chemo for Limited AIDS-related Kaposi’s Sarcoma. https://clinicaltrials.gov/ct2/show/
NCT01352117. (accessed 1 August 2016)
28. ClinicalTrials.gov. Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced 
AIDS-KS. https://clinicaltrials.gov/ct2/show/NCT01435018. (accessed 1 August 2016)
29**. Herce ME, Kalanga N, Wroe EB, et al. Excellent clinical outcomes and retention in care for 
adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated 
antiretroviral therapy in rural Malawi. J Int AIDS Soc. 2015; 18:19929. This study is the first 
description of integrated antiretroviral therapy and chemotherapy for HIV-associated Kaposi 
sarcoma in rural sub-Saharan Africa. With standardized protocols, clinical support to providers, 
and community health worker support to patients, 83% of patients were alive one year after 
chemotherapy initiation, results which are remarkably similar to patients treated in clinical trials 
at urban referral centers in the region. [PubMed: 26028156] 
30*. Byakwaga H, Hunt PW, Laker-Oketta M, et al. The Kynurenine Pathway of Tryptophan 
Catabolism and AIDS-Associated Kaposi Sarcoma in Africa. J Acquir Immune Defic Syndr. 
2015; 70:296–303. This case-control study describes a potentially novel pathogenic mechanism, 
immune activation through induction of the enzyme indoleamine 2,3-dioxygenase-1, which may 
be associated with lower risk of Kaposi sarcoma among HIV-infected Ugandans. [PubMed: 
26181812] 
31. Hosseinipour MC, Sweet KM, Xiong J, et al. Viral profiling identifies multiple subtypes of 
Kaposi’s sarcoma. MBio. 2014; 5:e01633–14. [PubMed: 25249280] 
32**. El-Mallawany NK, Kamiyango W, Slone JS, et al. Clinical Factors Associated with Long-Term 
Complete Remission versus Poor Response to Chemotherapy in HIV-Infected Children and 
Adolescents with Kaposi Sarcoma Receiving Bleomycin and Vincristine: A Retrospective 
Observational Study. PLoS One. 2016; 11:e0153335. This is a retrospective cohort description of 
Kaposi sarcoma among Malawian children, highlighting unique features of the pediatric form of 
the disease. Lymphadenopathy and peripheral blood cytopenias were common, and distinct 
clinical presentations were possibly associated with differential outcomes. [PubMed: 27082863] 
33. Cox CM, El-Mallawany NK, Kabue M, et al. Clinical characteristics and outcomes of HIV-infected 
children diagnosed with Kaposi sarcoma in Malawi and Botswana. Pediatr Blood Cancer. 2013; 
60:1274–80. [PubMed: 23487320] 
34. Chagaluka G, Stanley C, Banda K, et al. Kaposi’s sarcoma in children: an open randomised trial of 
vincristine, oral etoposide and a combination of vincristine and bleomycin. Eur J Cancer. 2014; 
50:1472–81. [PubMed: 24636877] 
35**. Rohner E, Wyss N, Heg Z, et al. HIV and human herpesvirus 8 co-infection across the globe: 
Systematic review and meta-analysis. Int J Cancer. 2016; 138:45–54. This is a systematic review 
describing assocations between HIV and Kaposi sarcoma-associated herpesvirus worldwide. The 
study found a two-fold increase in seroprevalence for Kaposi sarcoma-associated herpesvirus in 
HIV-infected versus HIV-uninfected people across all populations, but marked heterogeneity 
across studies and specific at-risk populations, highlighting a need to better understand 
transmission in different age and behavioral groups. [PubMed: 26175054] 
36**. Gatera M, Bhatt S, Ngabo F, et al. Successive introduction of four new vaccines in Rwanda: 
High coverage and rapid scale up of Rwanda’s expanded immunization program from 2009 to 
2013. Vaccine. 2016; 34:3420–6. This study decribes achievement of more than 90% coverage in 
Rwanda within five years of the national program for human papillomavirus vaccination among 
Chinula et al. Page 9
Curr Opin HIV AIDS. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
school-age girls. Keys to the program’s success included leadership from the Ministry of Health, 
and engagement of development partners, civil society organizations, and communities. 
[PubMed: 26704259] 
37**. Franceschi S, Chantal Umulisa M, Tshomo U, et al. Urine testing to monitor the impact of HPV 
vaccination in Bhutan and Rwanda. Int J Cancer. 2016; 139:518–26. This surveillance study was 
designed to assess early human papillomavirus vaccine effectivness in the first countries in Asia 
and Africa respectively to introduce national, school-based immunization programs. Signficant 
reductions in human papillomavirus prevalence were noted in both countries within two years of 
program initiation. [PubMed: 26991686] 
38*. Masika MM, Ogembo JG, Chabeda SV, et al. Knowledge on HPV Vaccine and Cervical Cancer 
Facilitates Vaccine Acceptability among School Teachers in Kitui County, Kenya. PLoS One. 
2015; 10:e0135563. This Kenya mixed methods study conducted in an area of school-based 
human papillomavirus immunization found moderate levels of teacher knowledge about the 
vaccine, and that level of teacher knowledge influenced whether or not they would recommend 
the vaccine. [PubMed: 26266949] 
39. Kojic EM, Kang M, Cespedes MS, et al. Immunogenicity and safety of the quadrivalent human 
papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis. 2014; 59:127–35. [PubMed: 
24723284] 
40. Clifford G, Franceschi S, Diaz M, et al. Chapter 3: HPV type-distribution in women with and 
without cervical neoplastic diseases. Vaccine. 2006; 24(Suppl 3):S3/26–34.
41**. Clifford GM, de Vuyst H, Tenet V, et al. Effect of HIV infection on human papillomavirus types 
causing invasive cervical cancer in Africa. J Acquir Immune Defic Syndr. 2016 This meta-
analysis examined human papillomavirus types among cervical cancer patients in Africa 
stratified by HIV status, and found similar proportions of cancers attributable to types 16/18 
(~70–75%) and other non-16/18 oncogenic types (~15–20%) irrespective of HIV status. 
42. Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of visual screening on cervical cancer 
incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet. 2007; 370:398–
406. [PubMed: 17679017] 
43. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. 
N Engl J Med. 2009; 360:1385–94. [PubMed: 19339719] 
44**. Parham GP, Mwanahamuntu MH, Kapambwe S, et al. Population-level scale-up of cervical 
cancer prevention services in a low-resource setting: development, implementation, and 
evaluation of the cervical cancer prevention program in Zambia. PLoS One. 2015; 10:e0122169. 
This study describes rapid scale-up of cervical cancer screening in Zamiba using visual 
inspection with acetic acid from 2006 to 2013. More than 100,000 women were screened with 
nearly 90% receiving same-day services, yielding detection rates of 17 and 7 per 100,000 women 
screened for high-grade dysplasia or cancer, and cancer, respectively. [PubMed: 25885821] 
45**. Kapambwe S, Sahasrabuddhe VV, Blevins M, et al. Implementation and Operational Research: 
Age Distribution and Determinants of Invasive Cervical Cancer in a “Screen-and-Treat” Program 
Integrated With HIV/AIDS Care in Zambia. J Acquir Immune Defic Syndr. 2015; 70:e20–6. This 
study from Zambia describes a four-fold increased risk of cervical cancer among HIV-positive 
women screened through the national program. Cervical cancer risk among screened HIV-
infected women peaked at age 35 and declined subsequently versus continuous increases with 
age among HIV-negative women. [PubMed: 26322673] 
46. Tsu V, Jeronimo J. Saving the World’s Women from Cervical Cancer. N Engl J Med. 2016; 
374:2509–11. [PubMed: 27355529] 
47. ClinicalTrials.gov. HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of 
CIN2+ in HIV-Infected Women. https://clinicaltrials.gov/ct2/show/NCT01315353. (accessed 1 
August 2016)
48. Abdel-Wahab M, Bourque JM, Pynda Y, et al. Status of radiotherapy resources in Africa: an 
International Atomic Energy Agency analysis. Lancet Oncol. 2013; 14:e168–75. [PubMed: 
23561748] 
49. ClinicalTrials.gov. Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated 
Locally Advanced Cervical Cancer. https://clinicaltrials.gov/ct2/show/NCT01590017. (accessed 1 
August 2016)
Chinula et al. Page 10
Curr Opin HIV AIDS. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
50*. Gopal S, Fedoriw Y, Kaimila B, et al. CHOP Chemotherapy for Aggressive Non-Hodgkin 
Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi. PLoS One. 2016; 
11:e0150445. This is the first prospective study describing CHOP for non-Hodgkin lymphoma in 
sub-Saharan Africa, which yielded 45% overall survival at 12 months among unselected patients, 
with outcomes driven principally by lymphoma prognostic characteristics rather than HIV status. 
[PubMed: 26934054] 
51. Bateganya MH, Stanaway J, Brentlinger PE, et al. Predictors of survival after a diagnosis of non-
Hodgkin lymphoma in a resource-limited setting: a retrospective study on the impact of HIV 
infection and its treatment. J Acquir Immune Defic Syndr. 2011; 56:312–9. [PubMed: 21350364] 
52. de Witt P, Maartens DJ, Uldrick TS, Sissolak G. Treatment outcomes in AIDS-related diffuse large 
B-cell lymphoma in the setting roll out of combination antiretroviral therapy in South Africa. J 
Acquir Immune Defic Syndr. 2013; 64:66–73. [PubMed: 23797692] 
53. Coghill AE, Newcomb PA, Madeleine MM, et al. Contribution of HIV infection to mortality 
among cancer patients in Uganda. AIDS. 2013; 27:2933–42. [PubMed: 23921614] 
54. ClinicalTrials.gov. Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma. 
https://clinicaltrials.gov/ct2/show/NCT02660710. (accessed 1 August 2016)
55. Mwanda WO, Orem J, Fu P, et al. Dose-modified oral chemotherapy in the treatment of AIDS-
related non-Hodgkin’s lymphoma in East Africa. J Clin Oncol. 2009; 27:3480–8. [PubMed: 
19470940] 
56. ClinicalTrials.gov. Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With 
Previously Untreated Stage III–IV HIV-Associated Non-Hodgkin Lymphoma. https://
clinicaltrials.gov/ct2/show/NCT01775475. (accessed 1 August 2016)
57*. Gichuhi S, Macharia E, Kabiru J, et al. Toluidine Blue 0.05% Vital Staining for the Diagnosis of 
Ocular Surface Squamous Neoplasia in Kenya. JAMA Ophthalmol. 2015; 133:1314–21. This 
Kenya study describes high sensitivity but low specificity for toluidine blue staining compared 
with histopathology, suggesting potential utility as a screening rather than diagnostic tool for 
ocular surface squamous neoplasia. [PubMed: 26378623] 
58*. Lecuona K, Stannard C, Hart G, et al. The treatment of carcinoma in situ and squamous cell 
carcinoma of the conjunctiva with fractionated strontium-90 radiation in a population with a high 
prevalence of HIV. Br J Ophthalmol. 2015; 99:1158–61. This study describes the addition of 
brachytherapy to resection of ocular surface squamous neoplasia in a South African setting with 
HIV prevalence, which was well tolerated and resulted in low rates of recurrence. [PubMed: 
25784215] 
Chinula et al. Page 11
Curr Opin HIV AIDS. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Key points
• Antiretroviral therapy is leading to epidemiologic 
transitions in low- and middle-income countries, with 
increasing cancer deaths, and transitions from AIDS-
defining cancers to non-AIDS defining cancers.
• Despite antiretroviral therapy scale-up, HIV-associated 
malignancies burden remains high including enormous 
AIDS-defining cancer burden in sub-Saharan Africa.
• Treatment and prevention that is appropriately tailored 
to low- and middle-income countries can be effective 
across a diverse range of geographic settings and 
specific HIV-associated malignancies.
• Continued investment for HIV-associated malignancies 
in low- and middle-income countries can catalyze a 
broad cancer care and research agenda which benefits 
HIV-positive and HIV-negative people.
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